Evofem Biosciences, Inc.
EVFM
$0.01
$0.00-8.54%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 21.87% | 4.23% | 3.67% | -2.51% | 3.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.87% | 4.23% | 3.67% | -2.51% | 3.70% |
| Cost of Revenue | 32.63% | 20.42% | 7.97% | -18.51% | -39.60% |
| Gross Profit | 18.98% | 0.24% | 2.66% | 2.62% | 28.43% |
| SG&A Expenses | -19.29% | -17.67% | -6.92% | -5.65% | -15.73% |
| Depreciation & Amortization | -58.31% | -19.39% | 141.86% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.24% | -30.68% | -24.00% | -25.08% | -36.27% |
| Operating Income | 23.26% | 118.75% | 71.06% | 60.89% | 73.67% |
| Income Before Tax | -94.80% | 104.44% | 31.57% | -110.31% | -106.12% |
| Income Tax Expenses | -- | -- | -- | -105.26% | -100.00% |
| Earnings from Continuing Operations | -94.83% | 104.41% | 31.54% | -110.31% | -106.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.83% | 104.41% | 31.54% | -110.31% | -106.13% |
| EBIT | 23.26% | 118.75% | 71.06% | 60.89% | 73.67% |
| EBITDA | 15.11% | 127.85% | 77.72% | 69.36% | 78.43% |
| EPS Basic | -99.61% | 98.84% | 91.62% | -100.40% | -100.27% |
| Normalized Basic EPS | -186.90% | 92.12% | 82.59% | 97.69% | 99.71% |
| EPS Diluted | -43.13% | 84.20% | 93.13% | 90.73% | 99.16% |
| Normalized Diluted EPS | -68.45% | 81.61% | 81.42% | 82.55% | 99.13% |
| Average Basic Shares Outstanding | 32.87% | 66.34% | 122.83% | 283.00% | 695.59% |
| Average Diluted Shares Outstanding | 222.50% | 1,617.69% | 270.56% | 171.23% | 929.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |